Introduction

Carnosinemia is a rare inherited metabolic disorder characterised by elevated levels of carnosine in the blood and urine.¹ Carnosine is a dipeptide, meaning it is composed of two amino acids, beta-alanine and histidine. This condition arises due to a deficiency in the enzyme carnosinase, which is responsible for breaking down carnosine in the body.² The primary cause of this enzyme deficiency is attributed to specific genetic alterations within the CNDP1 gene. Understanding these genetic defects is crucial for comprehending the underlying mechanisms of carnosinemia and its potential clinical implications. While carnosinemia is often considered a benign condition, its genetic basis provides insight into the intricate pathways of human metabolism and the impact of single-gene defects on biochemical processes.

Answering the main question

The genetic mutations behind carnosinemia primarily involve defects in the CNDP1 gene, which encodes the enzyme carnosinase 1 (also known as serum carnosinase or CNDP1). This enzyme is responsible for the hydrolysis, or breakdown, of carnosine into its constituent amino acids, beta-alanine and histidine.³ When pathogenic variants, which are permanent changes in the DNA sequence, occur within the CNDP1 gene, the resulting carnosinase enzyme may be non-functional, have reduced activity, or be absent altogether.⁴ This deficiency leads to an accumulation of carnosine in the bloodstream and urine, as the body is unable to process it effectively.⁵ Carnosinemia is inherited in an autosomal recessive pattern, meaning an individual must inherit two copies of the altered CNDP1 gene, one from each parent, to develop the condition.⁶

Read On

The Role of Carnosine and Carnosinase

Carnosine (beta-alanyl-L-histidine) is a naturally occurring dipeptide found in high concentrations in excitable tissues such as skeletal muscle and the brain.⁷ It plays several physiological roles, including acting as an antioxidant, a pH buffer, and a modulator of enzyme activity.⁸ As an antioxidant, carnosine helps to neutralise harmful free radicals, protecting cells from oxidative damage.⁸ Its buffering capacity contributes to maintaining stable pH levels, particularly important in muscle tissue during intense activity.⁷ Furthermore, carnosine can interact with various enzymes, influencing their catalytic rates and overall metabolic pathways.⁸ While the body can synthesise carnosine, it is also obtained through the diet, primarily from meat and poultry products.³⁷ In healthy individuals, carnosine is synthesised and subsequently broken down by carnosinase enzymes. There are two main types of carnosinases in humans: carnosinase 1 (CNDP1), which is found primarily in the serum (blood plasma) and brain, and carnosinase 2 (CNDP2), which is an intracellular enzyme found in various tissues, particularly the kidneys.⁹ Carnosinemia specifically refers to the deficiency of CNDP1, leading to systemic accumulation of carnosine.¹⁰ The presence of functional CNDP2 within cells means that intracellular carnosine metabolism may remain relatively unaffected, but the inability to break down carnosine in the bloodstream and cerebrospinal fluid leads to its excretion.¹¹

Genetic basis of CNDP1 defects

The CNDP1 gene is located on chromosome 18q22.3.¹² It comprises 14 exons, which are the coding regions of a gene, and spans approximately 30 kilobases.¹³ Numerous pathogenic variants within the CNDP1 gene have been identified that can lead to carnosinase deficiency. These variants can include missense mutations, where a single nucleotide change results in a different amino acid being incorporated into the enzyme; nonsense mutations, which introduce a premature stop codon, leading to a truncated and often non-functional protein; and frameshift mutations, caused by insertions or deletions of nucleotides that alter the reading frame of the gene, resulting in a completely different protein sequence or a premature stop codon.¹⁴ Missense mutations lead to the substitution of one amino acid for another in the carnosinase protein, potentially altering its three-dimensional structure and catalytic efficiency.¹⁴ Nonsense mutations introduce a premature stop signal, resulting in a shortened protein that is often non-functional and rapidly degraded.¹⁴ Frameshift mutations, caused by insertions or deletions of nucleotides not in multiples of three, drastically change the amino acid sequence downstream of the mutation, typically leading to a non-functional protein and premature termination.¹⁴ The consequence of these specific genetic changes is a significant reduction or complete absence of active carnosinase enzyme, preventing the proper breakdown of carnosine.¹⁷

The most commonly reported pathogenic variant associated with carnosinemia is a deletion of a specific region within the CNDP1 gene, leading to a non-functional enzyme.¹⁵ Other variants, while less common, also contribute to the spectrum of genetic defects observed in affected individuals. As an autosomal recessive disorder, individuals who are heterozygous for a CNDP1 pathogenic variant (i.e., they carry one normal copy and one altered copy of the gene) are typically asymptomatic carriers and do not exhibit carnosinemia.¹⁶ Only individuals who are homozygous for a pathogenic variant (i.e., they inherit two altered copies) or compound heterozygous (i.e., they inherit two different altered copies) will develop the condition.¹⁷ The specific type and location of the pathogenic variant can influence the residual enzyme activity, although the clinical correlation between genotype and phenotype in carnosinemia is not always straightforward, given its often benign nature.¹⁸

Clinical manifestations of carnosinemia

The clinical presentation of carnosinemia is highly variable, ranging from completely asymptomatic individuals to those with mild neurological symptoms.¹⁹ Historically, carnosinemia was first described in association with severe neurological impairments, including intellectual disability, epilepsy, and developmental delay.²⁰ However, subsequent research and broader screening programmes have revealed that many individuals with carnosinase deficiency are asymptomatic or exhibit only non-specific symptoms.²¹ This historical perspective, however, has been largely superseded by findings from more widespread biochemical screening, which have identified numerous asymptomatic individuals with carnosinase deficiency.²¹ This suggests that the presence of elevated carnosine alone does not necessarily lead to clinical symptoms, and the initial associations might have been coincidental or due to other underlying conditions.²⁴ Therefore, when neurological symptoms are observed in individuals with carnosinemia, a thorough diagnostic work-up is essential to identify any other potential causes, as the carnosinase deficiency itself may not be the primary driver of these clinical features.²⁵ This wide phenotypic variability suggests that carnosinase deficiency alone may not be the sole determinant of severe neurological outcomes, and other genetic or environmental factors might contribute to more pronounced clinical features.²²

When symptoms are present, they can include hypotonia (low muscle tone), spastic paraplegia (stiffness and weakness in the legs), microcephaly (abnormally small head), nystagmus (involuntary eye movements), and seizures.²³ However, it is important to note that these neurological signs are not universally present in all individuals with carnosinemia and can often be attributed to co-occurring conditions rather than directly to the carnosine accumulation itself.²⁴ The benign course observed in many individuals with carnosinemia has led some experts to question its classification as a primary disease, suggesting it might be a biochemical marker rather than a direct cause of severe pathology in many cases.²⁵

Diagnosis of carnosinemia

Diagnosis of carnosinemia typically begins with biochemical screening, often as part of newborn screening programmes, although it is not universally included.²⁶ Elevated levels of carnosine in the blood plasma and urine are the primary biochemical indicators.²⁷ This can be detected using techniques such as amino acid analysis via liquid chromatography-mass spectrometry or tandem mass spectrometry.²⁸ Confirmation of carnosinase deficiency can then be achieved by measuring the activity of the CNDP1 enzyme in serum samples.²⁹

The definitive diagnosis of carnosinemia is established through genetic testing, specifically by identifying pathogenic variants in the CNDP1 gene.³⁰ Molecular genetic testing, such as Sanger sequencing or next-generation sequencing panels that include the CNDP1 gene, can identify the specific genetic alterations responsible for the enzyme deficiency.³¹ Genetic testing is crucial not only for confirming the diagnosis but also for genetic counselling for affected families, allowing for the identification of carriers and informing reproductive choices.³²

Management and Prognosis

Given the often benign nature of carnosinemia, specific treatments are generally not required for most affected individuals.³³ There is currently no established standard treatment to reduce carnosine levels or to directly address the enzyme deficiency.³⁴ Management primarily focuses on symptomatic support if neurological issues are present, although these are often not directly linked to the carnosinemia itself.³⁵ Regular monitoring of neurodevelopmental milestones may be recommended for children diagnosed with the condition, particularly if any concerns arise.³⁶

Dietary restrictions are not typically advised, as carnosine is a natural component of meat and poultry, and its complete elimination from the diet is impractical and unnecessary given the variable clinical course.³⁷ Research into therapeutic strategies for rare metabolic disorders continues, but for carnosinemia, the focus remains on understanding its true clinical significance and differentiating it from other conditions that might present with similar neurological symptoms.³⁸ The long-term prognosis for individuals with carnosinemia is generally considered excellent, with many living full and healthy lives without significant health complications directly attributable to the condition.³⁹

Summary

Carnosinemia is a rare inherited metabolic condition characterised by elevated carnosine levels in the blood and urine, resulting from a deficiency of the CNDP1 enzyme. This deficiency is caused by pathogenic variants in the CNDP1 gene, inherited in an autosomal recessive manner. While historically linked to severe neurological symptoms, many affected individuals are asymptomatic, suggesting a wide range of clinical presentations. Diagnosis involves biochemical screening for elevated carnosine and is confirmed by genetic testing of the CNDP1 gene. Management is typically supportive, with no specific treatment required for most cases, and the prognosis is generally favourable.

FAQs

What is carnosine? 

Carnosine is a dipeptide found in muscle and brain tissue, composed of beta-alanine and histidine.

How is carnosinemia inherited? 

It is inherited in an autosomal recessive pattern, requiring two altered CNDP1 gene copies.

Are there always symptoms with carnosinemia? 

No, many individuals with carnosinemia are asymptomatic.

How is carnosinemia diagnosed? 

Diagnosis involves blood and urine tests for elevated carnosine, confirmed by genetic testing.

Is there a cure for carnosinemia? 

Currently, there is no specific cure, and treatment focuses on supportive care if symptoms are present.